安进(AMGN)创新药达唑达利贝治疗干燥综合征3期临床试验取得积极结果

金吾财讯
Nov 11

金吾财讯 | 生物制药巨头安进(AMGN)宣布,其创新药达唑达利贝(dazodalibep)在治疗干燥综合征(Sjögren's disease)的全球3期OASIZ-301临床试验中取得关键突破,两项主要给药方案均成功达到主要终点。作为目前全球首个在同类研究中同时改善全身疾病活动度与患者自述症状的3期临床试验,该成果后续有望填补该领域尚无FDA批准疗法的空白。试验结果显示,在648名中重度患者参与的研究中,在第48周时,每四周1500mg治疗组和每十二周3000mg治疗组的ESSDAI评分分别较基线下降了5.6分和5.2分,优于安慰剂组的3.8分(统计学差异显著)。同时,每四周一次的给药方案在第48周还改善了患者的口干及相关综合症状评分,并提升了唾液分泌量。此外,试验中观察到的大多数不良事件为轻至中度。分析人士指出,鉴于干燥综合征目前尚无有效获批治疗药物,达唑达利贝有望成为同类首创(First-in-Class)疗法,进一步丰富安进在免疫与炎症领域的创新产品矩阵。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10